AMGEN INC is 119.9x more valuable than Inhibrx, Inc. by market capitalization ($183.41 B vs $1.53 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | INBX | AMGN |
|---|---|---|
| Market cap | $1.53 B | $183.41 B |
| US-listed rank | #2307 | #79 |
| Revenue (latest FY) | $1.80M | $36.75B |
| Net income (latest FY) | -$241.36M | $7.71B |
| Net margin | -13408.9% | 21.0% |
| P/E (trailing FY) | - | 23.8 |
| SEC filings | 261 | 1,011 |
AMGEN INC is 119.9x more valuable than Inhibrx, Inc. by market capitalization ($183.41 B vs $1.53 B).
In their latest fiscal years, Inhibrx, Inc. reported $1.80M in revenue while AMGEN INC reported $36.75B.
Full pages: Inhibrx, Inc. and AMGEN INC, or browse the full rankings.